These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 16836561)

  • 1. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
    Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
    Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of small non-enveloped viruses by nanofiltration.
    Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
    Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
    Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS; Kim IS
    Korean J Lab Med; 2010 Feb; 30(1):45-50. PubMed ID: 20197722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
    Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
    Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
    Omar A; Kempf C
    Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
    Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
    Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.
    Azzi A; Maggi F; Zakrzewska K; Menconi MC; Di Pietro N; Salotti V; Farina C; Andreoli E; Fiorentino B; Angelini C; Corcioli F; Bendinelli M
    Transfusion; 2006 Jul; 46(7):1162-7. PubMed ID: 16836563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
    Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
    Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different susceptibility of B19 virus and mice minute virus to low pH treatment.
    Boschetti N; Niederhauser I; Kempf C; Stühler A; Löwer J; Blümel J
    Transfusion; 2004 Jul; 44(7):1079-86. PubMed ID: 15225251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
    Troccoli NM; McIver J; Losikoff A; Poiley J
    Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins.
    Modrof J; Berting A; Tille B; Klotz A; Forstner C; Rieger S; Aberham C; Gessner M; Kreil TR
    Transfusion; 2008 Jan; 48(1):178-86. PubMed ID: 17900278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.
    Koppelman MH; Cuijpers HT; Wessberg S; Valkeajärvi A; Pichl L; Schottstedt V; Saldanha J
    Transfusion; 2012 Jul; 52(7):1498-508. PubMed ID: 22587637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
    Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
    Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety issues for plasma derivatives and benefit from NAT testing.
    Willkommen H; Schmidt I; Löwer J
    Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
    Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
    J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.
    Roth NJ; Dichtelmüller HO; Fabbrizzi F; Flechsig E; Gröner A; Gustafson M; Jorquera JI; Kreil TR; Misztela D; Moretti E; Moscardini M; Poelsler G; More J; Roberts P; Wieser A; Gajardo R
    Transfusion; 2020 Nov; 60(11):2661-2674. PubMed ID: 32815181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scrapie removal using Planova virus removal filters.
    Tateishi J; Kitamoto T; Mohri S; Satoh S; Sato T; Shepherd A; Macnaughton MR
    Biologicals; 2001 Mar; 29(1):17-25. PubMed ID: 11482889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robustness of nanofiltration for increasing the viral safety margin of biological products.
    Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
    Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.